Clinical Trials Browser

Cystadenocarcinoma, Serous × pembrolizumab × Clear all

NCT04575961 2025-05-23

PERCEPTION

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Cystadenocarcinoma, Serous